Qualitative Computed Tomographic Features Predict Epidermal Growth Factor Receptor Mutations in Advanced Lung Adenocarcinoma
Introduction: Current guidelines recommend reflex testing for EGFR mutations in patients with advanced lung adenocarcinoma. Although tissue biopsy is considered the “gold standard” for EGFR mutation testing, it may not always be feasible in a small group of patients. Hence, this study aims to deter...
Saved in:
Main Author: | Chai, Chee Shee |
---|---|
Format: | Article |
Language: | English |
Published: |
Elsevier
2021
|
Subjects: | |
Online Access: | http://ir.unimas.my/id/eprint/34903/1/abstract.pdf http://ir.unimas.my/id/eprint/34903/ https://doi.org/10.1016/j.jtho.2021.01.1005 |
Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Epithelial-to-mesenchymal transition (EMT) causing acquired resistance to afatinib in a patient with epidermal growth factor receptor (EGFR)-mutant lung adenocarcinoma
by: Chai, Chee Shee, et al.
Published: (2018) -
Comparison of pattern of disease progression and prevalence of acquired T790M mutation in Malaysia patients with EGFR mutant lung adenocarcinoma upon failure of first-line afatinib, gefitinib and erlotinib
by: Chai, Chee Shee, et al.
Published: (2019) -
Predictors of Acquired T790M Mutation in Patients
Failing First- or Second-Generation Epidermal
Growth Factor Receptor-Tyrosine Kinase Inhibitors
by: Chai, Chee Shee, et al.
Published: (2020) -
Afatinib versus gefitinib or erlotinib in first-line setting for Malaysia patients with EGFR mutant advanced lung adenocarcinoma
by: Chai, Chee Shee, et al.
Published: (2019) -
Olmutinib in T790M-positive non-small cell lung cancer after failure of first-line epidermal growth factor receptor-tyrosine kinase inhibitor therapy: A global, phase 2 study
by: Park, Keunchil, et al.
Published: (2021)